Legend Biotech Corporation (LEGN) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

22/25

Growth 5 Margin 5 Expansion 4 Platform 3 Financial 5

latest quarter score

Earnings Reports

22
LEGN Q2 2026: CARVYKTI Sales Surge 50% Amid In Vivo CAR-T Clinical Breakthroughs
August 11, 2026
17
Legend Biotech (LEGN) Q1 2026: CARVICTI Ex-U.S. Sales Jump 200% as Early-Line Adoption Accelerates
May 12, 2026
20
Legend Biotech (LEGN) Q4 2025: Carvicti Doses Scale to 10,000 as Early-Line Penetration Accelerates
March 10, 2026
19
Legend Biotech (LEGN) Q3 2025: CARVICTI Sales Up 84% as Capacity Expansion Targets 10,000 Doses
November 12, 2025
18
Legend Biotech (LEGN) Q2 2025: CARVICTI Sales Jump 136%, Expanding Early-Line Adoption and Global Reach
August 11, 2025
20
Legend Biotech (LEGN) Q1 2025: CARVICTI Sales Up 135% as Early-Line Uptake Accelerates
July 07, 2025
14
Legend Biotech (LEGN) Q4 2024: CARVYKTI Sales Surge 110%, Doubling Capacity to Drive 2025 Growth
March 11, 2025

Browse all companies